Melanoma

• 

  Subject Areas on Research

  • "Thin" malignant melanoma: risk factors and clinical management. 
  • 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. 
  • A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. 
  • A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. 
  • A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants. 
  • A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. 
  • A global approach to tumor immunology. 
  • A methodology for utilization of predictive genomic signatures in FFPE samples. 
  • A model for pretest probability of lymph node metastasis from cutaneous Melanoma. 
  • A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. 
  • A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. 
  • A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. 
  • A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. 
  • A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. 
  • A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results. 
  • A natural history of melanoma: serial gene expression analysis. 
  • A panel of antibodies useful in the cytologic diagnosis of metastatic melanoma. 
  • A patient with newly diagnosed melanoma and pulmonary nodules. 
  • A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. 
  • A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. 
  • A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. 
  • A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma. 
  • A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. 
  • A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. 
  • A probabilistic analysis of mitotic counts in melanoma. 
  • A response to uveal melanoma: growth rate and prognosis. 
  • A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality. 
  • A simple method to cure established tumors by inflammatory killing of normal cells. 
  • A systematic review of clinical outcomes for patients diagnosed with skin cancer spinal metastases. 
  • A variant in FTO shows association with melanoma risk not due to BMI. 
  • Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal. 
  • Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. 
  • Accurate identification of proliferative index in melanocytic neoplasms with Melan-A/Ki-67 double stain. 
  • Acoustic radiation force impulse imaging of the abdomen: demonstration of feasibility and utility. 
  • Acral melanoma: a review of 185 patients with identification of prognostic variables. 
  • Active-specific immunization against melanoma: is the problem at the receiving end? 
  • Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. 
  • Advances in the care of the patient with malignant melanoma. 
  • Advances in the management of conjunctival melanoma. 
  • Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. 
  • Age as a prognostic factor in the malignant melanoma population. 
  • An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. 
  • An acrochordon-like melanoma metastasis. 
  • Analysis of 945 cases of pulmonary metastatic melanoma. 
  • Analysis of lymph nodal metastases in malignant melanoma using the poisson probability paradigm and Bayes rule. 
  • Analysis of prognosis and disease progression after local recurrence of melanoma. 
  • Analysis of prognostic variables which influence early and long-term response of pet animal tumors to radiation alone and radiation plus heat. 
  • Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. 
  • Anorectal melanoma: clinical characteristics and the role of abdominoperineal resection. 
  • Application of a panel of antiganglioside monoclonal antibodies to cytologic specimens. 
  • Application of posterior neck dissection in treating malignant melanoma of the posterior scalp. 
  • Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Association between a rare novel TP53 variant (rs78378222) and melanoma, squamous cell carcinoma of head and neck and lung cancer susceptibility in non-Hispanic Whites. 
  • Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk. 
  • Association between putative functional variants in the PSMB9 gene and risk of melanoma--re-analysis of published melanoma genome-wide association studies. 
  • Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. 
  • Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. 
  • Associations between smoking behavior-related alleles and the risk of melanoma. 
  • Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression. 
  • Autoantibodies against cell surface GRP78 promote tumor growth in a murine model of melanoma. 
  • Autofluorescence of choroidal melanoma in 51 cases. 
  • Autofluorescence of orange pigment overlying small choroidal melanoma. 
  • Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab. 
  • Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. 
  • BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. 
  • BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. 
  • Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. 
  • Bilateral pulmonary nodules in a 37-year-old woman with malignant melanoma. Pulmonary Langerhans cell histiocytosis (eosinophilic granuloma). 
  • Brief communication: melanoma-specific antibodies produced in monkeys by immunization with human melanoma cell lines. 
  • Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. 
  • C-reactive protein as a marker of melanoma progression. 
  • CD34 expression in desmoplastic melanoma. 
  • CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. 
  • CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. 
  • CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways. 
  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? 
  • Can completion lymph node dissection be avoided for a positive sentinel node in melanoma? 
  • Can surgeons improve survival in stage IV melanoma? 
  • Cancer and pregnancy: the clinician's perspective. 
  • Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. 
  • Cancer in pregnancy: a review of the literature. Part I. 
  • Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. 
  • Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy. 
  • Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. 
  • Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody. 
  • Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides. 
  • Central nervous system metastases in malignant melanoma. 
  • Changes in oligosaccharide chains of autoantibodies to GRP78 expressed during progression of malignant melanoma stimulate melanoma cell growth and survival. 
  • Characteristics of patients diagnosed with both melanoma and renal cell cancer. 
  • Characterization of CD8(-) HLA class I/epitope tetrameric complexes binding T cells. 
  • Characterization of a chimpanzee anti-human melanoma antiserum. 
  • Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. 
  • Characterization of melanoma cell membrane tumor-associated antigens using xenoserum, alloserum, and autoserum: I. immunofluorescence. 
  • Characterization of three restricted specificity monoclonal antibodies raised against the human glioma cell line D-54 MG. 
  • Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience. 
  • Choroidal metastatasis from a neuroendocrine tumor masquerading as choroidal melanoma. 
  • Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. 
  • Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, Lectureship. 
  • Circulating tumor cells in melanoma patients. 
  • Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. 
  • Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. 
  • Clinical applications of PET in oncology. 
  • Clinical applications of dendritic cell vaccines. 
  • Clinical correlates of NRAS and BRAF mutations in primary human melanoma. 
  • Clinical diagnosis of moles vs melanoma. 
  • Clinical experience with Tc-99m labeled (N2S2) anti-melanoma antibody fragments and single photon emission computed tomography. 
  • Clinical factors in the identification of small choroidal melanoma. 
  • Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. 
  • Clinicopathologic factors relating to surgical margins for cutaneous melanoma. 
  • Clinicopathologic study of 85 cases of melanoma of the female genitalia. 
  • Clinicopathological correlations in unilateral glaucoma. 
  • Clonal persistence and evolution during a decade of recurrent melanoma. 
  • Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. 
  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. 
  • Comparing in vivo pump-probe and multiphoton fluorescence microscopy of melanoma and pigmented lesions. 
  • Comparison of the use and results of sentinel lymph node biopsy in children and young adults with melanoma. 
  • Complete remission seven years after treatment for metastatic malignant melanoma. 
  • Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. 
  • Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates. 
  • Computed tomography in the detection of abdominal metastases from malignant melanoma. 
  • Congenital malignant melanoma. 
  • Conjunctival melanoma. 
  • Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. 
  • Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. 
  • Correlation between initial and long-term responses of spontaneous pet animal tumors to heat and radiation or radiation alone. 
  • Critical Assessment of Clinical Prognostic Tools in Melanoma. 
  • Current immunotherapeutic strategies in malignant melanoma. 
  • Current management of melanoma. 
  • Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. 
  • Curricular factors associated with medical students' practice of the skin cancer examination: an educational enhancement initiative by the integrated skin exam consortium. 
  • Cutaneous lymphatic drainage in patients with grossly involved nodal basins. 
  • Cutaneous melanoma of the head and neck. A review of 399 cases. 
  • Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase. 
  • Cytokinetic and molecular pharmacology studies of arabinosylcytosine in metastatic melanoma. 
  • Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells. 
  • D6.1, a murine antimelanoma monoclonal antibody from congenitally athymic nude mice immunized with purified melanoma tumor-associated antigen. 
  • DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. 
  • DNA ploidy of malignant melanoma determined by image cytometry of fresh frozen and paraffin-embedded tissue. 
  • DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. 
  • DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. 
  • Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas. 
  • Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. 
  • Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial. 
  • Dematiaceous fungi mimicking a conjunctival melanoma. 
  • Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. 
  • Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. 
  • Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. 
  • Diagnosis of a solitary cardiac metastasis from ocular melanoma. 
  • Diagnosis of metastatic malignant melanoma by fine needle aspiration biopsy: a clinical and pathologic correlation of 298 cases. 
  • Diagnosis of ocular surface lesions using ultra-high-resolution optical coherence tomography. 
  • Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. 
  • Differential expression of N-cadherin distinguishes a subset of metastasizing desmoplastic melanomas. 
  • Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process. 
  • Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection. 
  • Do not abandon the Breslow thickness. 
  • Early macular morphological changes following plaque radiotherapy for uveal melanoma. 
  • Early melanoma detection: nonuniform dermoscopic features and growth. 
  • Effect of Uveal Melanocytes on Choroidal Morphology in Rhesus Macaques and Humans on Enhanced-Depth Imaging Optical Coherence Tomography. 
  • Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. 
  • Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. 
  • Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. 
  • Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma. 
  • Endobronchial metastasis from primary anorectal melanoma. 
  • Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. 
  • Endoscopic ultrasound-guided fine-needle aspiration of intrathoracic and intra-abdominal spindle cell and mesenchymal lesions. 
  • Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. 
  • Entropy and information content of laboratory test results. 
  • Enzymatic susceptibility and spontaneous release of human melanoma tumor-associated antigens. 
  • Epidemiologic support for melanoma heterogeneity using the Surveillance, Epidemiology, and End Results Program. 
  • Epidemiologic support for melanoma heterogeneity using the surveillance, epidemiology, and end results program. 
  • Epidermal dynamics and patterns of intraepidermal melanoma. 
  • Epithelial, non-melanocytic and melanocytic proliferations of the ocular surface. 
  • Erythropoietin receptor contributes to melanoma cell survival in vivo. 
  • Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). 
  • Evaluation of 39 cases of pediatric cutaneous head and neck melanoma. 
  • Evaluation of new putative tumor markers for melanoma. 
  • Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. 
  • Exonuclease 1 (EXO1) gene variation and melanoma risk. 
  • Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. 
  • Experimental trials of immunotherapy for malignant melanoma. 
  • Exploring the association between melanoma and glioma risks. 
  • Expression of a melanoma-tumor-associated antigen as demonstrated by a monoclonal antibody (D6.1) in cytopathologic preparations of human tumor cells from effusions and needle aspirates. 
  • External ocular pigmentation. 
  • FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. 
  • Factors associated with elevated intraocular pressure in eyes with iris melanoma. 
  • Ferromagnetic hyperthermia and iodine 125 brachytherapy in the treatment of choroidal melanoma in a rabbit model. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Fine needle aspiration biopsy of metastatic melanoma. 
  • Fine needle aspiration biopsy of metastatic melanoma. A morphologic analysis of 174 cases. 
  • Fine-needle aspiration of choroidal melanoma metastatic to the liver. 
  • Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. 
  • Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. 
  • Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. 
  • Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. 
  • FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients. 
  • Frailty models with missing covariates. 
  • Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. 
  • Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma. 
  • Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. 
  • Future directions in regional treatment strategies for melanoma and sarcoma. 
  • GD3 expression by cultured human tumor cells of neuroectodermal origin. 
  • Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. 
  • Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. 
  • Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. 
  • Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. 
  • Generation of autologous tumor-specific cytotoxic T-cells using HLA-A region matched allogeneic melanoma. 
  • Generation of human IgG, IgA, and IgM anti-melanoma monoclonal antibodies utilizing lymphocytes of an actively immunized melanoma patient. 
  • Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. 
  • Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. 
  • Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells. 
  • Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. 
  • Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. 
  • Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival. 
  • Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival. 
  • Genetic variants in the PIWI-piRNA pathway gene DCP1A predict melanoma disease-specific survival. 
  • Genetic variants in the genes encoding rho GTPases and related regulators predict cutaneous melanoma-specific survival. 
  • Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. 
  • Genetic variants in the vitamin D pathway genes VDBP and RXRA modulate cutaneous melanoma disease-specific survival. 
  • Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. 
  • Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. 
  • Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. 
  • Genome-wide association study identifies nidogen 1 (NID1) as a susceptibility locus to cutaneous nevi and melanoma risk. 
  • Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. 
  • Genome-wide association study identifies three new melanoma susceptibility loci. 
  • Genomic and molecular profiling predicts response to temozolomide in melanoma. 
  • Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. 
  • Glycoconjugates and tumor metastasis. 
  • HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. 
  • HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients. 
  • Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. 
  • Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. 
  • Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. 
  • Health-related quality of life results from the phase III CheckMate 067 study. 
  • Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. 
  • High-Dose Interleukin-2: Evaluation of a Standardized Order Set for Biotherapy in an Intensive Care Unit
. 
  • High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. 
  • High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. 
  • High-fidelity mRNA amplification for gene profiling. 
  • High-field MR microscopy using fast spin-echoes. 
  • Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. 
  • Human T cells specifically activated against autologous malignant melanoma. 
  • Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases. 
  • Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. 
  • Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin. 
  • Human melanoma and leukemia associated antigens difined by nonhuman primate antisera. 
  • Human melanoma cell migration along capillary-like structures in vitro: a new dynamic model for studying extravascular migratory metastasis. 
  • Human melanoma growth in the peritoneal cavity of the athymic mouse--a model for in vivo study of cell-mediated immunity. 
  • Human melanoma-mediated inhibition of autologous CD4+ helper tumor-infiltrating lymphocyte growth in vitro. 
  • Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma. 
  • IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. 
  • Identification of a melanoma susceptibility locus and somatic mutation in TET2. 
  • Identification of a secreted Mr 95,000 glycoprotein in human melanocytes and melanomas by a melanocyte specific monoclonal antibody. 
  • Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV. 
  • Imaging microscopic pigment chemistry in conjunctival melanocytic lesions using pump-probe laser microscopy. 
  • Imaging of iris lesions with high-speed optical coherence tomography. 
  • Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen. 
  • Immune selection after antigen-specific immunotherapy of melanoma. 
  • Immunodiagnosis of melanoma using chimpanzee antihuman melanoma antiserum. 
  • Immunodiagnosis of tumors in vivo using radiolabeled monoclonal antibody A2B5. 
  • Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. 
  • Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. 
  • Immunotherapy for malignant melanoma with a tumor cell vaccine. 
  • Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. 
  • Implications of leukoregulin to autologous tumor-specific human T-cell populations. 
  • Importance of sentinel lymph node biopsy in patients with thin melanoma. 
  • Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. 
  • In vitro determination of thymidine-3H labeling index in human solid tumors. 
  • In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. 
  • In vivo evaluation of cell mediated immunity against human melanoma. 
  • In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody. 
  • In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. 
  • In-transit melanoma: the role of alkylating-agent resistance in regional therapy. 
  • Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. 
  • Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution. 
  • Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. 
  • Influence of mouse hepatitis virus on the growth of human melanoma in the peritoneal cavity of the athymic mouse. 
  • Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. 
  • Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. 
  • Inhibition of SUR1 decreases the vascular permeability of cerebral metastases. 
  • Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. 
  • Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells. 
  • Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk. 
  • Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. 
  • Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. 
  • Interferon-mediated protection of B16 melanoma cells from cytotoxicity by activated macrophages. 
  • Intracerebral malignant melanoma: high-field-strength MR imaging. 
  • Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment. 
  • Intraoperative 4-Dimensional Microscope-Integrated Optical Coherence Tomography-Guided 27-Gauge Transvitreal Choroidal Biopsy for Choroidal Melanoma. 
  • Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. 
  • Intrathoracic metastasis from an extrathoracic malignancy: a radiographic approach to patient evaluation. 
  • Intravitreal triamcinolone acetonide for acute radiation papillopathy. 
  • Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. 
  • Investigative studies in the diagnosis and treatment of melanoma. 
  • Investment in new technology research can save future health care dollars. 
  • Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. 
  • In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-4'-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma. 
  • Iris cyst secondary to latanoprost mimicking iris melanoma. 
  • Iris cyst secondary to latanoprost mimicking iris melanoma. 
  • Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. 
  • Isolated metastatic melanoma to the colon mimicking colon cancer. 
  • Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. 
  • Joint effect of multiple common SNPs predicts melanoma susceptibility. 
  • Juvenile malignant melanoma of the head and neck. 
  • Juvenile malignant melanoma. 
  • Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome. 
  • Kinetics of TCR use in response to repeated epitope-specific immunization. 
  • Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. 
  • Label-Free Imaging of Female Genital Tract Melanocytic Lesions With Pump-Probe Microscopy: A Promising Diagnostic Tool. 
  • Laparoscopic skill assessment of practicing surgeons prior to enrollment in a surgical trial of a new laparoscopic procedure. 
  • Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases. 
  • Late recurrence of malignant melanoma. Analysis of 168 patients. 
  • Lentigo maligna melanoma of the head and neck. 
  • Lethal "thin" malignant melanoma. Identifying patients at risk. 
  • Liver resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin: A multicentric study. 
  • Local control and distant metastases in primary canine malignant melanomas treated with hyperthermia and/or radiotherapy. 
  • Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. 
  • Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study. 
  • Long-term follow-up after uveal melanoma charged particle therapy. 
  • Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. 
  • Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. 
  • Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma. 
  • Lymphoscintigraphy for malignant melanoma. Surgical considerations. 
  • Lymphoscintigraphy in malignant melanoma: 99mTc antimony sulfur colloid. 
  • MGSA/GRO transcription is differentially regulated in normal retinal pigment epithelial and melanoma cells. 
  • MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. 
  • Macrophage migratory dysfunction in cancer. A mechanism for subversion of surveillance. 
  • Magnetic resonance imaging of juxtapapillary plaques in cadaver eyes. 
  • Malignant melanoma and pregnancy. 
  • Malignant melanoma and pregnancy. 
  • Malignant melanoma arising during pregnancy. A study of 100 patients. 
  • Malignant melanoma in black American and white American populations. A comparative review. 
  • Malignant melanoma in black Americans. A trend toward improved survival. 
  • Malignant melanoma in children. 
  • Malignant melanoma in the American black. 
  • Malignant melanoma in the elderly. 
  • Malignant melanoma metastatic to the gastrointestinal tract. 
  • Malignant melanoma of the mucous membranes: a review of 119 cases. 
  • Malignant melanoma presenting as a mediastinal mass. 
  • Malignant melanoma with a myxoid stroma: a diagnostic pitfall on fine-needle aspiration biopsy. 
  • Malignant melanoma. A multivariate analysis of prognostic factors. 
  • Malignant transformation of iris melanocytoma to iris ring melanoma. 
  • Management of recurrent melanoma of the extremity. 
  • Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. 
  • Massive Extraocular Extension of Uveal Melanoma. 
  • Mean of the ten largest nucleoli, microcirculation architecture, and prognosis of ciliochoroidal melanomas. 
  • Mechanism of immune response during immunotherapy. 
  • Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. 
  • Melanocytic tumors with intraepidermal melanophages: a report of five cases with review of 231 archived cutaneous melanocytic tumors. 
  • Melanoma arising in a skin graft. 
  • Melanoma brain metastasis: overview of current management and emerging targeted therapies. 
  • Melanoma metastasis masquerading as bilateral acoustic neuromas. 
  • Melanoma of the ear: treatment and survival probabilities based on 199 patients. 
  • Melanoma of the foot. 
  • Melanoma of the gallbladder: a review of cases seen at Duke University Medical Center. 
  • Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. 
  • Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. 
  • Melanoma, a tumor based on a mutant stem cell? 
  • Melanoma, version 4.2014. 
  • Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. 
  • Melanoma-associated retinopathy: a presenting sign of metastatic disease. 
  • Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. 
  • Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. 
  • Melanoma. 
  • Melanomas that defy clinical recognition. 
  • Melastatin expression and prognosis in cutaneous malignant melanoma. 
  • Metastatic ciliary body carcinoid tumor. 
  • Metastatic malignant melanoma with an unknown primary. 
  • Metastatic melanoma in the thorax: report of 130 patients. 
  • Metastatic melanoma of gastrocolic ligament treated with minimally invasive approach. 
  • Metastatic melanoma to the heart. 
  • Metastatic melanoma to the spine. Demographics, risk factors, and prognosis in 114 patients. 
  • Metastatic vs primary malignant neoplasms affecting the umbilicus: clinicopathologic features of 77 tumors. 
  • Microcirculation architecture of melanocytic nevi and malignant melanomas of the ciliary body and choroid. A comparative histopathologic and ultrastructural study. 
  • Microcirculation architecture of metastases from primary ciliary body and choroidal melanomas. 
  • Microcirculation patterns other than loops and networks in choroidal and ciliary body melanomas. 
  • Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. 
  • Mitotic rate in melanoma: a reexamination. 
  • Modeling cancer progression via pathway dependencies. 
  • Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. 
  • Modulation of in vitro autologous melanoma-specific cytotoxic T-cell responses by phorbol dibutyrate and ionomycin. 
  • Modulation of resistance to regional chemotherapy in the extremity melanoma model. 
  • Molecular alternations in uveal melanoma. 
  • Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. 
  • Molecular classification of cutaneous malignant melanoma by gene expression profiling. 
  • Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. 
  • Molecular staging of malignant melanoma: correlation with clinical outcome. 
  • Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center. 
  • Mucosal melanoma of the head and neck. 
  • Mucosal melanoma. 
  • Multiple assay characterization of murine monoclonal antimelanoma antibodies. 
  • Multiple lung nodules in a woman with a history of melanoma. 
  • Multiple primary melanoma: incidence and risk factors in 283 patients. 
  • Multivariate procedures to describe clinical staging of melanoma. 
  • Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. 
  • Mutations of the BRAF gene in human cancer. 
  • NCCN Guidelines Insights: Melanoma, Version 3.2016. 
  • Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. 
  • Natural and orthogonal model for estimating gene-gene interactions applied to cutaneous melanoma. 
  • Neoadjuvant use of ipilimumab in locally advanced melanoma. 
  • Neovascular glaucoma associated with an iris melanoma. A clinicopathologic report. 
  • Neurofibromatosis and neural crest neoplasms: primary acquired melanosis and malignant melanoma of the conjunctiva. 
  • Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. 
  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. 
  • Nivolumab: Immunotherapy in Malignant Melanoma. 
  • No association between Parkinson disease alleles and the risk of melanoma. 
  • Non-specific and specific active immunotherapy in a B16 murine melanoma system. 
  • Non-specific and specific immunotherapy in patients with melanoma. 
  • Nonlinear microscopy of eumelanin and pheomelanin with subcellular resolution. 
  • Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. 
  • Obesity-related genetic variants, human pigmentation, and risk of melanoma. 
  • Ocular neoplastic disease. 
  • On the interplay of telomeres, nevi and the risk of melanoma. 
  • Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. 
  • Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. 
  • Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. 
  • Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? 
  • Optimizing regional infusion treatment strategies for melanoma of the extremities. 
  • Optimizing regional therapy for melanoma. 
  • Outcomes of 27-Gauge Vitrectomy-Assisted Choroidal and Subretinal Biopsy. 
  • Overview of melanoma vaccines and promising approaches. 
  • PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. 
  • PGC-1 coactivators regulate MITF and the tanning response. 
  • PHGDH amplification and altered glucose metabolism in human melanoma. 
  • Paraganglioma-like dermal melanocytic tumor: a unique entity distinct from cellular blue nevus, clear cell sarcoma, and cutaneous melanoma. 
  • Paraneoplastic retinopathy with multiple detachments of the neurosensory retina and autoantibodies against interphotoreceptor retinoid binding protein (IRBP) in cutaneous melanoma. 
  • Patient age in Spitz nevus and malignant melanoma: implication of Bayes rule for differential diagnosis. 
  • Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma. 
  • Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. 
  • Pediatric melanoma. 
  • Pediatric melanoma: a single-institution experience of 150 patients. 
  • Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. 
  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. 
  • Perinatal Considerations in Women With Previous Diagnosis of Cancer. 
  • Perineural spread of melanoma demonstrated by F-18 FDG PET With MRI and pathologic correlation. 
  • Perineural tumor extension to the cavernous sinus from superficial facial carcinoma: CT manifestations. 
  • Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma. 
  • Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial. 
  • Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI. 
  • Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 
  • Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. 
  • Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. 
  • Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma. 
  • Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. 
  • Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. 
  • Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) 
  • Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. 
  • Pigmented Lesions of the Nervous System and the Neural Crest: Lessons From Embryology. 
  • Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. 
  • Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. 
  • Polymorphisms of nucleotide excision repair genes predict melanoma survival. 
  • Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. 
  • Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. 
  • Positron emission tomography scanning in malignant melanoma. 
  • Possibilities of immunotherapy and gene therapy for malignant melanoma. 
  • Predicting disease progression after regional therapy for in-transit melanoma. 
  • Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. 
  • Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. 
  • Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. 
  • Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide. 
  • Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. 
  • Prevention and early detection of melanoma: a surgeon's perspective. 
  • Prevention of melanoma by recognition of its precursors. 
  • Primary chondroid melanoma. 
  • Primary intracranial melanoma presenting as a suprasellar tumor. 
  • Primary intramedullary melanocytoma of the spinal cord: case report. 
  • Primary malignant melanoma of the esophagus. 
  • Primary malignant melanoma of the scrotum. 
  • Probabilistic issues with sentinel lymph nodes in malignant melanoma. 
  • Prognosis for recurrent stage I malignant melanoma. 
  • Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. 
  • Prognostic factors in head and neck melanoma. Effect of lesion location. 
  • Progressive enlargement of cavity within melanoma masquerading as iris cyst. 
  • Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases. 
  • Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. 
  • Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. 
  • Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. 
  • Prospects for cellular immunotherapy for metastatic melanoma. 
  • Proton-beam irradiated epithelioid cell melanoma of the ciliary body. 
  • Pulmonary metastasectomy for metastatic malignant melanoma. 
  • Pump-Probe Microscopic Imaging of Jurassic-Aged Eumelanin. 
  • Pump-probe imaging differentiates melanoma from melanocytic nevi. 
  • Punch biopsy vs. shave biopsy: a comparison of margin status of clinically atypical pigmented lesions. 
  • Quality of life after isolated limb infusion for in-transit melanoma of the extremity. 
  • Quantifying melanin spatial distribution using pump-probe microscopy and a 2-D morphological autocorrelation transformation for melanoma diagnosis. 
  • Quiescent phenotype of tumor-specific CD8+ T cells following immunization. 
  • Radiologic, endoscopic and surgical considerations of malignant melanoma metastatic to the small intestine. 
  • Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. 
  • Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. 
  • Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. 
  • Randomized trial of hyperthermia and radiation for superficial tumors. 
  • Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. 
  • Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. 
  • Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2. 
  • Recommendations for the reporting of tissues removed as part of the surgical treatment of common malignancies of the eye and its adnexa. The Association of Directors of Anatomic and Surgical Pathology. 
  • Recurrent malignant melanoma of the penis. 
  • Recurrent malignant melanoma: the identification of prognostic factors to predict survival. 
  • Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. 
  • Regional therapies for in-transit disease. 
  • Regression of uveal melanoma after plaque radiotherapy and thermotherapy based on chromosome 3 status. 
  • Regulation of cell division and of tyrosinase in B16 melanoma cells by imidazole: a possible role for the concept of metabolite gene regulation in mammalian cells. 
  • Relation between the microcirculation architecture and the aggressive behavior of ciliary body melanomas. 
  • Relationship between disease-free interval and survival in patients with recurrent melanoma. 
  • Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. 
  • Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. 
  • Retinal tear and detachment after transpupillary thermotherapy for choroidal melanoma. 
  • Role of high resolution optical coherence tomography in diagnosing ocular surface squamous neoplasia with coexisting ocular surface diseases. 
  • Role of surgical intervention in the management of intestinal metastases from malignant melanoma. 
  • S100 A6 immunohistochemical staining for spindle cell and desmoplastic melanomas. 
  • SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. 
  • SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma. 
  • Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. 
  • Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial. 
  • Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. 
  • Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. 
  • Sector laser photocoagulation for the prevention of macular edema after plaque radiotherapy for uveal melanoma: a pilot study. 
  • Segmenting skin lesions with partial-differential-equations-based image processing algorithms. 
  • Segregation analysis in cutaneous malignant melanoma/dysplastic nevus syndrome families. 
  • Selection and validation of endogenous reference genes using a high throughput approach. 
  • Selection of patients with melanoma brain metastases for aggressive treatment. 
  • Sentinel lymph node biopsy following a rotational flap. 
  • Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. 
  • Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. 
  • Sentinel lymph node biopsy in melanoma of the head and neck. 
  • Sentinel lymph node biopsy is a prognostic measure in pediatric melanoma. 
  • Sentinel lymph node detection using laser-assisted indocyanine green dye lymphangiography in patients with melanoma. 
  • Sentinel node biopsy for head and neck melanoma: a systematic review. 
  • Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. 
  • Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. 
  • Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. 
  • Sex related survival differences in instances of melanoma. 
  • Sex steroid receptor analysis in human melanoma. 
  • Short-term kinetics of tumor antigen expression in response to vaccination. 
  • Sinonasal melanoma: survival and prognostic implications based on site of involvement. 
  • Skeletal metastases of melanoma. 
  • Skin melanoma. Cured fraction and survival time as functions of thickness, site, histologic type, age, and sex. 
  • Small choroidal melanoma with chromosome 3 monosomy on fine-needle aspiration biopsy. 
  • Solar elastosis in cutaneous melanoma. 
  • Solitary pulmonary metastases in high-risk melanoma patients: a prospective comparison of conventional and computed tomography. 
  • Solubilization and partial isolation of human melanoma tumor-associated antigens. 
  • Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. 
  • Specific active immunotherapy for melanoma. 
  • Specific cytotoxic antibody in the sera of patients with melanoma. 
  • Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. 
  • Stage II malignant melanoma: presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients. 
  • Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. 
  • Statistical analysis of the concordance of immunohistochemical stains with the final diagnosis in spitzoid neoplasms. 
  • Status of activation of circulating vaccine-elicited CD8+ T cells. 
  • Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma. 
  • Studies on the distribution of blood flow in amelanotic melanoma and reticulum cell lymphosarcoma during growth. 
  • Studies on the enhanced interaction of halodeoxyuridine-substituted DNAs with H1 histones and other polypeptides. 
  • Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin. 
  • Subungual melanoma of the great toe in a Hispanic male with Down syndrome: a case report and review of the literature. 
  • Subungual melanoma. A review of 93 cases with identification of prognostic variables. 
  • Surgical management of aberrant sentinel lymph node drainage in cutaneous melanoma. 
  • Surgical management of cutaneous melanoma: current practice and impact on prognosis. 
  • Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. 
  • Surgical margins around primary cutaneous melanomas. 
  • Surgical therapy of cutaneous melanoma. 
  • Surveillance strategies in the follow-up of melanoma patients: too much or not enough? 
  • Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. 
  • Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. 
  • Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity. 
  • Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells. 
  • Systematic identification of signaling pathways with potential to confer anticancer drug resistance. 
  • T-cell-directed cancer vaccines: the melanoma model. 
  • THE HALO NEVUS. 
  • Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. 
  • Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. 
  • Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. 
  • Teenage acne and cancer risk in US women: A prospective cohort study. 
  • Telomere length connects melanoma and glioma predispositions. 
  • Temozolomide and treatment of malignant glioma. 
  • Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. 
  • The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. 
  • The DNA repair capacity of melanoma cells. 
  • The Escherichia coli subtilase cytotoxin A subunit specifically cleaves cell-surface GRP78 protein and abolishes COOH-terminal-dependent signaling. 
  • The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. 
  • The Skin Cancer Objective Structured Clinical Examination (SCOSCE): A multi-institutional collaboration to develop and validate a clinical skills assessment for melanoma. 
  • The annual risk of melanoma progression. Implications for the concept of cure. 
  • The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy. 
  • The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. 
  • The dynamics of death in melanoma. 
  • The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost. 
  • The efficacy of anti-PD-1 agents in acral and mucosal melanoma. 
  • The efficacy of full-lung tomography in the detection of early metastatic disease from melanoma. 
  • The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases. 
  • The importance of total number of sentinel lymph nodes in patients with stage N0 cutaneous melanoma. 
  • The long-term clinical course of patients with cutaneous melanoma. 
  • The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. 
  • The orderly progression of melanoma nodal metastases. 
  • The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles. 
  • The prevalence and characteristics of congenital pigmented lesions in newborn babies in Oxford. 
  • The prognostic significance of recall antigen testing in melanoma patients. 
  • The prognostic value of tumor blood vessel morphology in primary uveal melanoma. 
  • The rational clinical examination. Does this patient have a mole or a melanoma? 
  • The relationship between blood IL-12p40 level and melanoma progression. 
  • The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. 
  • The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. 
  • The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. 
  • The role of resection in the management of melanoma metastatic to the adrenal gland. 
  • The role of whole brain radiation therapy in the management of melanoma brain metastases. 
  • The spectrum of small bowel melanoma. 
  • The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma. 
  • The tumor biology of melanoma nodal metastases. 
  • The tumor dormant state. 
  • The use of non-human primates for production of antisera to human tumor-associated antigens. 
  • The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. 
  • Therapeutic and prognostic considerations of head and neck melanoma. 
  • Thin malignant melanomas of the head and neck. 
  • Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. 
  • Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. 
  • Time trends of incidence of age-associated diseases in the US elderly population: Medicare-based analysis. 
  • Timing of sentinel lymph node mapping after lymphoscintigraphy. 
  • Towards a genomic-based diagnosis. 
  • Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. 
  • Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. 
  • Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. 
  • Treatment of human melanoma hepatic metastases in nude mice with human cytotoxic T lymphocytes. 
  • Treatment of in-transit melanoma: an opportunity to discover critical knowledge. 
  • Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor. 
  • Two-day lymphoscintigraphic imaging for melanoma. 
  • Ultrastructure and clinicopathologic correlation of idiopathic preretinal macular fibrosis. 
  • Unique proteins defined by monoclonal antibodies specific for human melanoma. Some potential clinical applications. 
  • Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. 
  • Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. 
  • Use of gene expression and pathway signatures to characterize the complexity of human melanoma. 
  • Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma. 
  • Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. 
  • Uveal prolapse following cataract extraction simulating melanoma. 
  • Validation of delayed sentinel lymph node mapping for melanoma. 
  • Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population. 
  • Virtual bronchoscopy for directing transbronchial needle aspiration of hilar and mediastinal lymph nodes: a pilot study. 
  • What is your diagnosis? Spitzoid melanoma. 
  • What's new in general surgery: surgical oncology. 
  • [Adjuvant therapy of surgically removed stage I melanoma]. 
  • [Basis for a specific-active immunotherapy in malignant melanoma]. 
  • [In vivo evaluation of cellular immunity in melanoma patients against melanoma]. 
  • [Longitudinal melanic nail bands (melanonychia): report of 22 cases]. 
  • [Malignant melanoma: hepatic intra-arterial chemotherapy]. 
  • cDNA arrays and the enigma of melanoma immune responsiveness. 
  • p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. 
  • p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. 
• 

  Keywords of People

  • Bennett, Vann, George B. Geller Professor for Research in Molecular Biology in the School of Medicine, Duke Cancer Institute
  • Hanks, Brent A., Assistant Professor of Medicine, Medicine, Medical Oncology
  • Lee, Walter T, Associate Professor of Surgery, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Mosca, Paul Joseph, Associate Professor of Surgery, Surgery, Advanced Oncologic and Gastrointestinal Surgery
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology, Nuclear Medicine
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine, Immunology
  • Yan, Hai, Henry S. Friedman Professor of Neuro-Oncology in the School of Medicine, Pathology
  • Yoo, Sua, Associate Professor of Radiation Oncology, Radiation Oncology